CytoSorbents sees FY18 revenue at least $22.3M, consensus $22.71M

The company expects to announce record results including: Full year 2018 total revenue of at least $22.3M, with additional 2018 grant revenue expected upon finalization of invoicing; Full-year product sales in 2018 of approximately $20.2M, an increase of approximately 51% compared to $13.4M in 2017, and record Q4 2018 product sales of approximately $5.4M; 2018 blended gross product margins in excess of 72%, mixing higher margin direct sales and lower margin distributor and partner sales; More than 56,000 CytoSorb cumulative treatments delivered, up from 35,000 treatments a year ago; End-of-year cash position of approximately $22.3M (12/31/18).
https://thefly.com/landingPageNews.php?id=2844703